Treatment of Metastatic Triple-Negative Breast Cancer
The Pharma Data
MARCH 25, 2021
SG contains a genotoxic component and can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. Embryo-Fetal Toxicity.
52 
Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
The Pharma Data
APRIL 7, 2021
The incidence of Grade 3-4 neutropenia in genotyped patients was 69% in patients homozygous for the UGT1A1*28, 48% in patients heterozygous for the UGT1A1*28 allele and 46% in patients homozygous for the wild-type allele. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells.
Trodelvy® for the Treatment of Metastatic Urothelial Cancer
The Pharma Data
APRIL 14, 2021
The incidence of Grade 3-4 neutropenia in genotyped patients was 67% in patients homozygous for the UGT1A1*28, 46% in patients heterozygous for the UGT1A1*28 allele and 46% in patients homozygous for the wild-type allele. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells.
Let's personalize your content